Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants

  • Borrego-Écija, Sergi
  • Turon-Sans, Janina
  • Ximelis, Teresa
  • Aldecoa, Iban
  • Molina-Porcel, Laura
  • Povedano, Mónica
  • Gamez Carbonell, Josep
Proteïna TDP-43; Esclerosi lateral amiotròfica; Demència frontotemporal, Proteína TDP-43; Esclerosis lateral amiotrófica; Demencia frontotemporal, TDP-43 protein; Amyotrophic lateral sclerosis; Frontotemporal dementia, Cognitive impairment and behavioral changes in amyotrophic lateral sclerosis (ALS) are now recognized as part of the disease. Whether it is solely related to the extent of TDP-43 pathology is currently unclear. We aim to evaluate the influence of age, genetics, neuropathological features, and concomitant pathologies on cognitive impairment in ALS patients. We analyzed a postmortem series of 104 ALS patients and retrospectively reviewed clinical and neuropathological data. We assessed the burden and extent of concomitant pathologies, the role of APOE ε4 and mutations, and correlated these findings with cognitive status. We performed a logistic regression model to identify which pathologies are related to cognitive impairment. Cognitive decline was recorded in 38.5% of the subjects. Neuropathological features of frontotemporal lobar degeneration (FTLD) were found in 32.7%, explaining most, but not all, cases with cognitive impairment. Extent of TDP-43 pathology and the presence of hippocampal sclerosis were associated with cognitive impairment. Mutation carriers presented a higher burden of TDP-43 pathology and FTLD more frequently than sporadic cases. Most cases (89.4%) presented some degree of concomitant pathologies. The presence of concomitant pathologies was associated with older age at death. FTLD, but also Alzheimer’s disease, were the predominant underlying pathologies explaining the cognitive impairment in ALS patients. In sum, FTLD explained the presence of cognitive decline in most but not all ALS cases, while other non-FTLD related findings can influence the cognitive status, particularly in older age groups., SBE is a recipient of the Rio-Hortega post-residency grant from the Instituto de Salud Carlos III, Spain. This study was partially funded by Fundació Marató de TV3 (grant no. 20141610 to EG and no. 20143710 to RRG) and Fondo Europeo de Desarrollo Regional (FEDER) (PI15/01618 to RRG). AA is funded by Departament de Salut de la Generalitat de Catalunya, Pla estratègic de recerca i innovació en salut (PERIS) 2016–2020 (SLT002/16/00329). JG is recipient of the Instituto de Salud Carlos III-FEDER grants (PI16/01673 and PI19/00593)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Haplotype Analysis of the First A4V-SOD1 Spanish Family: Two Separate Founders or a Single Common Founder?

  • Garcia Rodríguez, Cecilia
  • Vidal Taboada, José Manuel
  • Syriani Casagrande, Enrique
  • Salvadó Figueras, Maria
  • Morales, Miguel
  • Gamez Carbonell, Josep
A4V; SOD1; Esclerosi lateral amiotròfica, A4V; SOD1; Esclerosis lateral amiotrófica, A4V; SOD1; Amyotrophic lateral sclerosis, Despite the genetic heterogeneity reported in familial amyotrophic lateral sclerosis (ALS) (fALS), Cu/Zn superoxide-dismutase (SOD1) gene mutations are the second most common cause of the disease, accounting for around 20% of all families (ALS1) and isolated sporadic cases (sALS). At least 186 different mutations in the SOD1 gene have been reported to date. The possibility of a single founder and separate founders have been investigated for D90A (p.D91A) and A4V (p.A5V), the most common mutations worldwide. High-throughput single nucleotide polymorphism genotyping studies have suggested two founders for A4V (one for the Amerindian population and another for the European population) although the possibility that the two populations are descended from a single ancient founder cannot be ruled out. We used 15 genetic variants spanning the human chromosome 21 from the SOD1 gene to the SCAF4 gene, comparing them with the population reference panels, to demonstrate that the first A4V Spanish pedigree shared the genetic background reported in the European population., This study has been supported by Instituto de Salud Carlos III (grant numbers PIS-FEDER PI16/01673 and PI19/00593). JG and JV-T are the recipients of grant 2017SGR00939 from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Haplotype Analysis of the First A4V-SOD1 Spanish Family, Two Separate Founders or a Single Common Founder?

  • Garcia, Cecilia
  • Vidal-Taboada, José Manuel
  • Syriani, Enrique
  • Salvado, María
  • Morales, Miguel
  • Gamez, Josep|||0000-0003-3127-7486
Despite the genetic heterogeneity reported in familial amyotrophic lateral sclerosis (ALS) (fALS), Cu/Zn superoxide-dismutase (SOD1) gene mutations are the second most common cause of the disease, accounting for around 20% of all families (ALS1) and isolated sporadic cases (sALS). At least 186 different mutations in the SOD1 gene have been reported to date. The possibility of a single founder and separate founders have been investigated for D90A (p.D91A) and A4V (p.A5V), the most common mutations worldwide. High-throughput single nucleotide polymorphism genotyping studies have suggested two founders for A4V (one for the Amerindian population and another for the European population) although the possibility that the two populations are descended from a single ancient founder cannot be ruled out. We used 15 genetic variants spanning the human chromosome 21 from the SOD1 gene to the SCAF4 gene, comparing them with the population reference panels, to demonstrate that the first A4V Spanish pedigree shared the genetic background reported in the European population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cognitive decline in amyotrophic lateral sclerosis, Neuropathological substrate and genetic determinants

  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Ximelis, Teresa
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Povedano, Mónica
  • Rubio, Miguel Angel|||0000-0002-0495-6240
  • Gamez, Josep|||0000-0003-3127-7486
  • Cano, Antonio
  • Paré-Curell, Martí|||0000-0002-0627-5350
  • Bajo, Lorena
  • Sotoca Fernández, Javier|||0000-0003-3400-1434
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Balasa, Mircea|||0000-0002-1795-4228
  • Antonell, Anna|||0000-0002-3286-8459
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Gelpi, Ellen|||0000-0003-2948-4187
Cognitive impairment and behavioral changes in amyotrophic lateral sclerosis (ALS) are now recognized as part of the disease. Whether it is solely related to the extent of TDP-43 pathology is currently unclear. We aim to evaluate the influence of age, genetics, neuropathological features, and concomitant pathologies on cognitive impairment in ALS patients. We analyzed a postmortem series of 104 ALS patients and retrospectively reviewed clinical and neuropathological data. We assessed the burden and extent of concomitant pathologies, the role of APOE ε4 and mutations, and correlated these findings with cognitive status. We performed a logistic regression model to identify which pathologies are related to cognitive impairment. Cognitive decline was recorded in 38.5% of the subjects. Neuropathological features of frontotemporal lobar degeneration (FTLD) were found in 32.7%, explaining most, but not all, cases with cognitive impairment. Extent of TDP-43 pathology and the presence of hippocampal sclerosis were associated with cognitive impairment. Mutation carriers presented a higher burden of TDP-43 pathology and FTLD more frequently than sporadic cases. Most cases (89.4%) presented some degree of concomitant pathologies. The presence of concomitant pathologies was associated with older age at death. FTLD, but also Alzheimer's disease, were the predominant underlying pathologies explaining the cognitive impairment in ALS patients. In sum, FTLD explained the presence of cognitive decline in most but not all ALS cases, while other non-FTLD related findings can influence the cognitive status, particularly in older age groups.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy

  • Statland, J.M.|||0000-0003-0790-5315
  • Campbell, C.
  • Desai, Urvi|||0000-0001-5196-7201
  • Karam, C.
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Guptill, J.T.
  • Korngut, L.
  • Genge, A.
  • Tawil, R.N.
  • Elman, Lauren B.
  • Joyce, N.C.
  • Wagner, K.R.
  • Manousakis, Georgios|||0000-0002-8309-9426
  • Amato, A.A.
  • Butterfield, R.J.|||0000-0002-8452-7189
  • Shieh, P.B.|||0000-0001-7145-7663
  • Wicklund, M.
  • Gamez, Josep|||0000-0003-3127-7486
  • Bodkin, C.
  • Pestronk, Alan|||0000-0002-8991-5770
  • Weihl, C.C.
  • Vílchez Padilla, Juan J.
  • Johnson, N.E.|||0000-0002-3917-4257
  • Mathews, K.D.
  • Miller, B.
  • Leneus, A.
  • Fowler, M.
  • van de Rijn, M.
  • Attie, K.M.
Facioscapulohumeral muscular dystrophy (FSHD) is a slowly progressive muscular dystrophy without approved therapies. In this study we evaluated whether locally acting ACE-083 could safely increase muscle volume and improve functional outcomes in adults with FSHD. Participants were at least 18 years old and had FSHD1/FSHD2. Part 1 was open label, ascending dose, assessing safety and tolerability (primary objective). Part 2 was randomized, double-blind for 6 months, evaluating ACE-083240 mg/muscle vs placebo injected bilaterally every 3 weeks in the biceps brachii (BB) or tibialis anterior (TA) muscles, followed by 6 months of open label. Magnetic resonance imaging measures included total muscle volume (TMV; primary objective), fat fraction (FF), and contractile muscle volume (CMV). Functional measures included 6-minute walk test, 10-meter walk/run, and 4-stair climb (TA group), and performance of upper limb midlevel/elbow score (BB group). Strength, patient-reported outcomes (PROs), and safety were also evaluated. Parts 1 and 2 enrolled 37 and 58 participants, respectively. Among 55 participants evaluable in Part 2, the least-squares mean (90% confidence interval, analysis of covariance) treatment difference for TMV was 16.4% (9.8%-23.0%) in the BB group (P <.0001) and 9.5% (3.2%-15.9%) in the TA group (P =.01). CMV increased significantly in the BB and TA groups and FF decreased in the TA group. There were no consistent improvements in functional or PRO measures in either group. The most common adverse events were mild or moderate injection-site reactions. Significant increases in TMV with ACE-083 vs placebo did not result in consistent functional or PRO improvements with up to 12 months of treatment.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants

  • Borrego-Écija, Sergi
  • Turon-Sans, Janina
  • Ximelis, Teresa
  • Aldecoa, Iban
  • Molina-Porcel, Laura
  • Povedano, Mónica
  • Gamez Carbonell, Josep
Proteïna TDP-43; Esclerosi lateral amiotròfica; Demència frontotemporal, Proteína TDP-43; Esclerosis lateral amiotrófica; Demencia frontotemporal, TDP-43 protein; Amyotrophic lateral sclerosis; Frontotemporal dementia, Cognitive impairment and behavioral changes in amyotrophic lateral sclerosis (ALS) are now recognized as part of the disease. Whether it is solely related to the extent of TDP-43 pathology is currently unclear. We aim to evaluate the influence of age, genetics, neuropathological features, and concomitant pathologies on cognitive impairment in ALS patients. We analyzed a postmortem series of 104 ALS patients and retrospectively reviewed clinical and neuropathological data. We assessed the burden and extent of concomitant pathologies, the role of APOE ε4 and mutations, and correlated these findings with cognitive status. We performed a logistic regression model to identify which pathologies are related to cognitive impairment. Cognitive decline was recorded in 38.5% of the subjects. Neuropathological features of frontotemporal lobar degeneration (FTLD) were found in 32.7%, explaining most, but not all, cases with cognitive impairment. Extent of TDP-43 pathology and the presence of hippocampal sclerosis were associated with cognitive impairment. Mutation carriers presented a higher burden of TDP-43 pathology and FTLD more frequently than sporadic cases. Most cases (89.4%) presented some degree of concomitant pathologies. The presence of concomitant pathologies was associated with older age at death. FTLD, but also Alzheimer’s disease, were the predominant underlying pathologies explaining the cognitive impairment in ALS patients. In sum, FTLD explained the presence of cognitive decline in most but not all ALS cases, while other non-FTLD related findings can influence the cognitive status, particularly in older age groups., SBE is a recipient of the Rio-Hortega post-residency grant from the Instituto de Salud Carlos III, Spain. This study was partially funded by Fundació Marató de TV3 (grant no. 20141610 to EG and no. 20143710 to RRG) and Fondo Europeo de Desarrollo Regional (FEDER) (PI15/01618 to RRG). AA is funded by Departament de Salut de la Generalitat de Catalunya, Pla estratègic de recerca i innovació en salut (PERIS) 2016–2020 (SLT002/16/00329). JG is recipient of the Instituto de Salud Carlos III-FEDER grants (PI16/01673 and PI19/00593)
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Haplotype Analysis of the First A4V-SOD1 Spanish Family: Two Separate Founders or a Single Common Founder?

  • Garcia Rodríguez, Cecilia
  • Vidal Taboada, José Manuel
  • Syriani Casagrande, Enrique
  • Salvadó Figueras, Maria
  • Morales, Miguel
  • Gamez Carbonell, Josep
A4V; SOD1; Esclerosi lateral amiotròfica, A4V; SOD1; Esclerosis lateral amiotrófica, A4V; SOD1; Amyotrophic lateral sclerosis, Despite the genetic heterogeneity reported in familial amyotrophic lateral sclerosis (ALS) (fALS), Cu/Zn superoxide-dismutase (SOD1) gene mutations are the second most common cause of the disease, accounting for around 20% of all families (ALS1) and isolated sporadic cases (sALS). At least 186 different mutations in the SOD1 gene have been reported to date. The possibility of a single founder and separate founders have been investigated for D90A (p.D91A) and A4V (p.A5V), the most common mutations worldwide. High-throughput single nucleotide polymorphism genotyping studies have suggested two founders for A4V (one for the Amerindian population and another for the European population) although the possibility that the two populations are descended from a single ancient founder cannot be ruled out. We used 15 genetic variants spanning the human chromosome 21 from the SOD1 gene to the SCAF4 gene, comparing them with the population reference panels, to demonstrate that the first A4V Spanish pedigree shared the genetic background reported in the European population., This study has been supported by Instituto de Salud Carlos III (grant numbers PIS-FEDER PI16/01673 and PI19/00593). JG and JV-T are the recipients of grant 2017SGR00939 from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya.